Welcome to our dedicated page for Inotiv SEC filings (Ticker: NOTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating toxicology tables, animal-welfare disclosures, and segment margins across Discovery and Safety Assessment versus Research Models can turn Inotiv’s SEC filings into a 300-page puzzle. If you have ever asked, “Where do I find Inotiv insider trading Form 4 transactions or the latest Inotiv quarterly earnings report 10-Q filing?” this page is built for you.
Stock Titan’s AI reads every 10-K, 10-Q, 8-K, and S-4 the moment they post to EDGAR. Our platform extracts cash-flow swings, upcoming FDA audit risks, and contractual earn-out details, then serves plain-English dashboards. You will see Inotiv Form 4 insider transactions real-time, debt-covenant changes, and revenue by service line—all in one view. The same engine powers quick answers to the common search, “Inotiv SEC filings explained simply,” delivering side-by-side trend charts and an Inotiv earnings report filing analysis you can skim in minutes.
Need deeper dives? Use our AI summary links for understanding Inotiv SEC documents with AI, or jump straight to red-lined PDFs. Track an Inotiv executive stock transactions Form 4 alert before material announcements, open an Inotiv annual report 10-K simplified for five-year segment KPIs, review the Inotiv proxy statement executive compensation for pay-for-performance alignment, or scan an Inotiv 8-K material events explained digest after unexpected CRO contract wins. From real-time feeds to curated insights, every filing type is covered so you can focus on decisions, not document hunts.
Inotiv, Inc. (NOTV) Form 144 reports a proposed sale of 6,000 common shares through The Charles Schwab Corporation with an aggregate market value of $10,000. The filing lists 34,354,251 shares outstanding and an approximate sale date of 09/02/2025. The shares were acquired as restricted stock that vested on 04/01/2023. The filing also discloses prior sales by the same person of 2,000 shares on 07/01/2025 (gross proceeds $3,620) and 2,000 shares on 08/01/2025 (gross proceeds $3,818). The signer represents they have no undisclosed material nonpublic information.
Inotiv, Inc. (NASDAQ: NOTV) is filing an S-3 shelf prospectus to permit future offerings of securities, including an at-the-market equity program managed by Jefferies. The company describes two operating segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS), which together provide nonclinical drug development services and research animals/products to pharmaceutical, device, academic and government clients. The prospectus states net proceeds are expected to be used for working capital and general corporate purposes, and sales may occur from time to time at varying prices under a sales agreement with Jefferies that pays up to 3.0% commission. The registrant discloses an auditor’s report from Ernst & Young LLP that includes an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern and notes material weaknesses in internal control over financial reporting. The filing warns investors of immediate dilution risk, variability of proceeds from ATM sales, and typical forward-looking statement cautions.
FAQ
What is the current stock price of Inotiv (NOTV)?
What is the market cap of Inotiv (NOTV)?
